GSK (GSK) News Today $33.36 -0.10 (-0.30%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Connor Clark & Lunn Investment Management Ltd. Acquires 456,319 Shares of GSK plc (NYSE:GSK)Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of GSK plc (NYSE:GSK - Free Report) by 420.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 564,934 shares of the pharmaceuNovember 21 at 5:33 AM | marketbeat.comPathstone Holdings LLC Acquires 26,707 Shares of GSK plc (NYSE:GSK)Pathstone Holdings LLC raised its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 12.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 246,614 shares of the pharmaceutical company's stock after purchasing an aNovember 21 at 4:20 AM | marketbeat.comBrokerages Set GSK plc (NYSE:GSK) Price Target at $43.25November 21 at 3:04 AM | americanbankingnews.comStock Traders Buy High Volume of Call Options on GSK (NYSE:GSK)GSK plc (NYSE:GSK - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors purchased 26,518 call options on the company. This is an increase of 326% compared to the average daily volume of 6,227 call options.November 19 at 11:51 AM | marketbeat.comGSK hails positive results for linerixibat in treating relentless itchNovember 19 at 5:48 AM | lse.co.ukGSK plc (NYSE:GSK) Shares Acquired by Natixis Advisors LLCNatixis Advisors LLC lifted its stake in GSK plc (NYSE:GSK - Free Report) by 20.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 500,495 shares of the pharmaceutical company's stock after acquiring an additional 83,433 shares during the quarNovember 19 at 4:45 AM | marketbeat.comGSK drug meets main goal in late-stage study to treat relentless itchNovember 19 at 2:19 AM | reuters.comMedicus Pharma unveils ex-GSK and Pfizer senior as chief medical officerNovember 18 at 12:03 PM | proactiveinvestors.comGSK plc (NYSE:GSK) Shares Sold by LMR Partners LLPLMR Partners LLP reduced its position in shares of GSK plc (NYSE:GSK - Free Report) by 39.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,019,192 shares of the pharmaceutical company's stock after selling 1,312,266 sNovember 18 at 7:29 AM | marketbeat.comEquity Investment Corp Grows Position in GSK plc (NYSE:GSK)Equity Investment Corp lifted its stake in shares of GSK plc (NYSE:GSK - Free Report) by 1.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,496,254 shares of the pharmaceutical company'November 18 at 6:31 AM | marketbeat.comDurham non-profit among several to receive GSK fundsNovember 18 at 2:50 AM | msn.comGSK plc (NYSE:GSK) Receives Consensus Rating of "Moderate Buy" from AnalystsGSK plc (NYSE:GSK - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the compaNovember 18 at 1:09 AM | marketbeat.comGSK (NYSE:GSK) Sees Unusually-High Trading Volume - Here's What HappenedNovember 17, 2024 | americanbankingnews.comAs Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.November 15, 2024 | forbes.comGSK (NYSE:GSK) Sees Unusually-High Trading Volume - Time to Buy?GSK (NYSE:GSK) Sees Strong Trading Volume - Still a Buy?November 15, 2024 | marketbeat.comGSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)November 15, 2024 | seekingalpha.comGSK (NYSE:GSK) Stock Rating Lowered by Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a report on Friday.November 15, 2024 | marketbeat.comBell Bank Sells 24,678 Shares of GSK plc (NYSE:GSK)Bell Bank lessened its stake in shares of GSK plc (NYSE:GSK - Free Report) by 14.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,911 shares of the pharmaceutical company's stock after selling 24,67November 14, 2024 | marketbeat.comArjuna Capital Has $3.23 Million Position in GSK plc (NYSE:GSK)Arjuna Capital raised its position in shares of GSK plc (NYSE:GSK - Free Report) by 144.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 78,934 shares of the pharmaceutical company's stock after purchasinNovember 13, 2024 | marketbeat.comGlaxoSmithKline (GSK) was downgraded to a Hold Rating at JefferiesNovember 13, 2024 | markets.businessinsider.comGSK downgraded to Hold from Buy at JefferiesNovember 12, 2024 | msn.comVesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson's DiseaseNovember 12, 2024 | finance.yahoo.comGSK Steps Up Parkinson’s Focus With US Biotech DealNovember 12, 2024 | msn.comGSK (NYSE:GSK) Downgraded to Hold Rating by Jefferies Financial GroupJefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday.November 12, 2024 | marketbeat.comGSK to quit lobbying group BIO, STAT reportsNovember 11, 2024 | markets.businessinsider.comDiabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with DiabetesNovember 11, 2024 | finance.yahoo.comStockman Wealth Management Inc. Acquires 15,024 Shares of GSK plc (NYSE:GSK)Stockman Wealth Management Inc. boosted its holdings in GSK plc (NYSE:GSK - Free Report) by 7.7% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 209,517 shares of the pharmaceutical company's stock after acquiring an adNovember 10, 2024 | marketbeat.comLegacy Capital Wealth Partners LLC Acquires 20,211 Shares of GSK plc (NYSE:GSK)Legacy Capital Wealth Partners LLC lifted its holdings in GSK plc (NYSE:GSK - Free Report) by 103.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 39,769 shares of the pharmaceutical company's stock after acquiring an additional 20,211 sharesNovember 10, 2024 | marketbeat.comCWA Asset Management Group LLC Makes New $1.91 Million Investment in GSK plc (NYSE:GSK)CWA Asset Management Group LLC purchased a new stake in GSK plc (NYSE:GSK - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 46,607 shares of the pharmaceutical company's stock, valued at approximately $1,905,000. Several otherNovember 10, 2024 | marketbeat.comProvident Trust Co. Has $161.62 Million Holdings in GSK plc (NYSE:GSK)Provident Trust Co. lifted its holdings in GSK plc (NYSE:GSK - Free Report) by 1.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,953,602 shares of the pharmaceutical company'sNovember 9, 2024 | marketbeat.comBarclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)November 8, 2024 | markets.businessinsider.comGSK to invest $800M in Pennsylvania drug expansionNovember 8, 2024 | finance.yahoo.comPfizer, GSK, Moderna struggle in a shrinking RSV vaccine marketNovember 7, 2024 | msn.comHarvest Portfolios Group Inc. Acquires New Stake in GSK plc (NYSE:GSK)Harvest Portfolios Group Inc. acquired a new stake in GSK plc (NYSE:GSK - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 49,100 shares of the pharmaceutical company's stock, valued at approNovember 7, 2024 | marketbeat.comJanney Montgomery Scott LLC Lowers Position in GSK plc (NYSE:GSK)Janney Montgomery Scott LLC decreased its stake in shares of GSK plc (NYSE:GSK - Free Report) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 294,806 shares of the pharmaceutical company's stock aftNovember 7, 2024 | marketbeat.comWe Think You Can Look Beyond GSK's (LON:GSK) Lackluster EarningsNovember 6, 2024 | uk.finance.yahoo.comCanada approves GSK's RSV vaccine for adults aged 50 to 59November 5, 2024 | reuters.comVan ECK Associates Corp Buys 56,843 Shares of GSK plc (NYSE:GSK)Van ECK Associates Corp lifted its position in shares of GSK plc (NYSE:GSK - Free Report) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 736,510 shares of the pharmaceutical company's stock afNovember 5, 2024 | marketbeat.comUS Bancorp DE Buys 25,781 Shares of GSK plc (NYSE:GSK)US Bancorp DE boosted its stake in GSK plc (NYSE:GSK - Free Report) by 12.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 236,770 shares of the pharmaceutical company's stock after acquiring an additional 25,7November 3, 2024 | marketbeat.comJFS Wealth Advisors LLC Boosts Stake in GSK plc (NYSE:GSK)JFS Wealth Advisors LLC grew its position in shares of GSK plc (NYSE:GSK - Free Report) by 1,429.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 29,426 shares of the pharmaceutical company's stock after acquiring an additional 27,502 shares during the pNovember 1, 2024 | marketbeat.comGlaxoSmithKline (GSK) Receives a Hold from Kepler CapitalNovember 1, 2024 | markets.businessinsider.comGSK downgraded to Neutral from Buy at GuggenheimOctober 31, 2024 | markets.businessinsider.comGSK PLC (GSK) Q3 2024 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...October 31, 2024 | finance.yahoo.comGSK reaffirms 2024 core EPS growth view 10%-12%October 31, 2024 | markets.businessinsider.comGSK (NYSE:GSK) Downgraded by Guggenheim to "Neutral"Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research report on Thursday.October 31, 2024 | marketbeat.comGSK plc 2024 Q3 - Results - Earnings Call PresentationOctober 30, 2024 | seekingalpha.comGSK (NYSE:GSK) Shares Gap Down - Here's What HappenedGSK (NYSE:GSK) Shares Gap Down - Should You Sell?October 30, 2024 | marketbeat.comGSK (NYSE:GSK) Updates FY 2024 Earnings GuidanceGSK (NYSE:GSK) updated its FY 2024 earnings guidance. The company provided EPS guidance of 1.710-1.740 for the period, compared to the consensus estimate of 4.060. The company also issued revenue guidance of $40.9 billionillion-$41.7 billionillion, compared to the consensus estimate of $41.5 billionillion.October 30, 2024 | marketbeat.comGSK: Earnings Confirm It's On Track To Meet GuidanceOctober 30, 2024 | seekingalpha.comDrugmaker GSK Posts Loss On Zantac FalloutOctober 30, 2024 | barrons.com Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. GSK Media Mentions By Week GSK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSK News Sentiment▼0.600.45▲Average Medical News Sentiment GSK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GSK Articles This Week▼1712▲GSK Articles Average Week Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Novartis News Today AstraZeneca News Today Sanofi News Today Takeda Pharmaceutical News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Summit Therapeutics News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:GSK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GSK Stock Alerts